ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GV-971

Also written as “Sodium oligo-mannurarate 900mg”, “Sodium Oligomannate Capsules” and “Sodium Oligomannate Capsules (GV-971)”.

Its studies are mostly in Alzheimer Disease · Cognitive Dysfunction, led by 2 companies.

Drug pageGV-971: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 16, 20218 company-led studies, 3 open or runningNext primary completion: Jun 2029 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Green Valley (Shanghai) Pharmaceuticals43 open or runningphase 4since May 16, 2021Aug 11, 2020Jun 2029phase 4 · NCT05908695
Shanghai Greenvalley Pharmaceuticalits history only40 open or runningphase 3since Nov 13, 2014Sep 30, 2011none ahead
  • Named in fosun pharma’s own pipeline as GV-971, phase 3, as of Sep 21, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Green Valley (Shanghai) Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2020First study: phase 3 study in Alzheimer DiseaseFirst studyNCT04520412 · 2,046 enrolled · United States, Australia, Canada and more
  2. May 16, 2021Phase 4 study in Alzheimer DiseaseNCT05058040 · 2,500 enrolled · China
  3. Dec 2, 2021Phase 4 study in Alzheimer DiseaseNCT05181475 · 800 enrolled · China
  4. May 31, 2023Phase 4 study in Alzheimer DiseaseNCT05908695 · 1,312 planned · China

Ahead

  1. Jun 2029Primary completion: phase 4 study in Alzheimer DiseaseNCT05908695

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Green Valley (Shanghai) Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05908695Alzheimer Disease · China4RecruitingJun 20291,312
NCT05181475Alzheimer Disease · China4Active, not recruitingJan 2025800
NCT05058040Alzheimer Disease · China4Active, not recruitingJan 20252,500
NCT04520412Alzheimer Disease · United States, Australia, Canada and more3SuspendedDec 20252,046

How it is read

Names in the registry

  • “GV-971”, 4 entries
  • “Sodium oligo-mannurarate 900mg”, 2 entries
  • “Sodium Oligomannate Capsules”, 1 entry
  • “Sodium Oligomannate Capsules (GV-971)”, 1 entry
  • “Sodium oligo-mannurarate 600mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.